CorMedix
Price chart
Anonymous reader poll. Unscientific, not investment advice.
✦ StockVane Quant Insights how this is computed
- Below its 200-day average and near the bottom of the universe on momentum.
- Signal has read STRONG SELL for 3 weeks.
- Its last 4 Sell calls were followed by roughly flat moves (-2%) three months out.
- Recent price momentum is -40.9% on average (3-month/1-year).
- Main-fund capital flow has been a net outflow over the last 45 sessions.
- Short interest has fallen to 18.2% of float.
- Analyst tilt is Buy.
- Price is below its 20-day average and below its 60-day average.
- The 20-day average is below the 60-day average, a short-term downtrend.
Computed by a StockVane algorithm from historical price, valuation and analyst data - not a person, not a forecast guarantee, and not investment advice.
Factor grades
Ranked against 2848 U.S. stocks StockVane covers.
Last computed: 2026-11-22 02:27 UTC
Data coverage: 5 of 6 factors. Missing data is not a zero score.
The radar needs all six factors. Available grades are shown below.
Valuation B+
How expensive the stock is versus earnings, sales and its own 5-year history.
| P/E (TTM) | 8.2x | Better than 87% |
| Price / Sales | 0.9x | Better than 80% |
| P/E vs own 5-yr range | 89th pctl | Better than 15% |
Growth N/A
How fast revenue, profit and free cash flow are compounding.
Not enough data to grade this factor.
Profitability A+
How much profit the business keeps from each dollar of sales and capital.
| Gross margin | 88.5% | Better than 96% |
| Operating margin | 48.2% | Better than 97% |
| Net margin | 52.0% | Better than 97% |
| Return on equity | 66.2% | Better than 96% |
| Return on invested capital | 50.4% | Better than 99% |
Momentum D
Recent price strength, skipping the latest month to avoid short-term noise.
| 3-month return | -35.7% | Better than 13% |
| 6-month return | -34.0% | Better than 15% |
| 12-month return (ex latest month) | -18.9% | Better than 16% |
| Distance below 52-week high | 59.5% | Better than 11% |
Financial Health B+
Balance-sheet strength: leverage, liquidity and interest coverage.
| Current ratio | 2.1x | Better than 58% |
| Debt to assets | 18.0% | Better than 58% |
| Interest coverage | 54.9x | Better than 90% |
| Free cash flow / net income | 106.0% | Better than 42% |
Analyst View A+
What the Street thinks: share of Buy ratings and upside to the average target.
| Analysts rating Buy | 100.0% | Better than 77% |
| Upside to average target | 165.7% | Better than 91% |
Grades are relative rankings, not forecasts: A+ is the top 5% of the covered stocks on a factor, F the bottom 3%. Valuation is not adjusted for sector. Background recomputation is scheduled every 6 hours; actual computation time is shown above, and source datasets have different reporting dates. Not investment advice or tailored to your financial situation.
Performance
Key statistics
Price & volume
- Prev close
- 5.08
- Open
- 4.96
- Day range
- 4.95 - 5.32
- Avg price
- 5.18
- Volume
- 3.61M
- Turnover
- 18.70M
- Turnover ratei
- 5.36%
- Volume ratioi
- 1.42
- Amplitudei
- 7.19%
- 52-week rangei
- 4.47 - 13.02
Valuation
- P/Ei
- 2.58
- P/E (TTM)i
- 8.23
- P/Bi
- 0.91
- EPSi
- 2.04
- Book value / shi
- 5.81
- Net profit
- 162.26M
- Net assets
- 461.72M
Share structure
- Market cap
- 419.16M
- Float capi
- 355.21M
- Shares out
- 79.54M
- Float sharesi
- 67.40M
Dividend & listing
- Div yield (TTM)i
- 0.00%
- Dividend (TTM)
- 0.00
- Listing date
- --
59.5% below the 52-week high
Trading activity
Net capital flow main funds, last 45 sessions
-2.79M net over the window
Short interest
- Shares short
- 14.21M
- % of floati
- 18.23%
- Days to coveri
- 8.44
- As of
- 2026-10-30
Frequently asked questions
What is the current stock price of CorMedix (CRMD)?
CorMedix last traded at 5.27. This page shows a periodic quote snapshot. Check the displayed quote time.
What is CorMedix's market cap?
About 419.16M.
What is the P/E ratio of CorMedix?
The trailing twelve-month P/E is 8.23. The Valuation tab shows it against the stock's own five-year range.
Does CorMedix pay a dividend?
CorMedix does not currently pay a regular dividend.
Is CorMedix a buy according to analysts?
The consensus of 5 analysts is a Buy rating, with an average 12-month price target of 14.00, which implies 165.7% upside from the current price. This is not investment advice.
What is CorMedix's StockVane Quant Rating?
The StockVane Momentum strategy currently rates CorMedix a E (Strong Sell). Below its 200-day average and near the bottom of the universe on momentum. Not investment advice.
Quote time 2026-11-20 19:30:06 · For reference only, not investment advice and not tailored to your situation.
CorMedix discussion 0 comments